Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b/2 Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Forma Therapeutics, Inc.
Participants in this trial will be recruited according to the following classifications -
Cohort 1a and 1b: Glioma
Cohort 1a and 1b: Glioblastoma Multiforme
Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)
Cohort 3a and 3b: Chondrosarcoma
Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma
Cohort 5a: Other Solid Tumors With IDH1 Mutations.
All participants in Cohorts 1a-5a will receive FT-2102 as a 150mg capsule, administered as per the protocol defined frequency and dose. In Cohorts 1b and 3b, Azacitidine will also be administered, as per site's standard of care (SOC). In Cohort 2b Nivolumab will be administered as per the site's SOC, in addition to FT-2102. Participants in Cohort 4b will receive Gemcitabine and Cisplatin will be administered per site's SOC in addition to FT-2102.